Processing...
Clinical Trials for Prostate Cancer
Search
Search
There are 204 active trials for advanced/metastatic prostate cancer.
Click on a trial to see more information.
204 trials meet filter criteria.
Sort by:
HealthScout AI summary: Veterans with oligometastatic or oligo-recurrent prostate cancer (1–10 PSMA/fluciclovine/choline PET-detected lesions; ECOG ≤2) are randomized to standard systemic therapy (ADT ± first-generation antiandrogen; optional intensification with docetaxel, abiraterone, apalutamide, or enzalutamide; de novo cases also get prostate RT) with or without PET-directed local therapy to all sites (SBRT/surgery and salvage local therapy when feasible). No investigational drugs; compares addition of metastasis-directed therapy to contemporary systemic care.
ClinicalTrials.gov ID: NCT04787744
HealthScout AI summary: Men with mCRPC after ≥1 second-generation ARSI (± up to two taxane lines), PSMA-PET–avid disease, and ECOG 0–1 receive pembrolizumab (PD‑1 inhibitor) plus 177Lu‑PSMA‑617 radioligand therapy, with two initial Lu‑PSMA doses then adaptive re-dosing at PSA rise until progression/toxicity. Excludes prior PSMA-directed therapy or checkpoint inhibitors; allows treated/stable brain metastases.
ClinicalTrials.gov ID: NCT05766371
HealthScout AI summary: Adults with metastatic castration-resistant prostate adenocarcinoma after ≥2 prior lines (including a next-generation AR inhibitor) and castrate testosterone receive lymphodepleting cyclophosphamide/fludarabine followed by a single infusion of autologous STEAP1-directed CAR T cells plus continuous enzalutamide. The investigational product is a CAR T therapy targeting STEAP1 to direct T‑cell cytotoxicity against STEAP1-expressing tumors; key exclusions include active autoimmune disease requiring immunosuppression, uncontrolled infection, and untreated/symptomatic brain metastases.
ClinicalTrials.gov ID: NCT06236139
HealthScout AI summary: This trial involves patients with advanced or metastatic solid tumors expressing Nectin-4, including urothelial carcinoma, triple-negative breast cancer, non-small cell lung cancer, and ovarian cancer, who have exhausted standard therapy options. It evaluates LY4052031, an antibody-drug conjugate that targets Nectin-4 to deliver a topoisomerase I inhibitor, aiming to assess its safety, tolerability, and efficacy in these patients.
ClinicalTrials.gov ID: NCT06465069
HealthScout AI summary: This trial enrolls patients aged 18 and older with advanced solid tumors, including RCC, CRPC, NSCLC, SCCHN, CRC, endometrial, and ovarian cancers, who have failed or are ineligible for standard treatments, to evaluate TT-10, an adenosine A2A receptor antagonist, and TT-4, an adenosine A2B receptor antagonist, administered as single agents and in combination.
ClinicalTrials.gov ID: NCT04969315
HealthScout AI summary: Eligible patients are adults with advanced or metastatic solid tumors—including urothelial, triple negative breast, non-small cell lung, esophageal, pancreatic, ovarian, cervical (squamous), head and neck squamous cell, and prostate cancers—who have exhausted standard therapies and have ECOG 0–1. All participants receive intravenous LY4101174, a novel antibody-drug conjugate targeting nectin-4 and delivering a topoisomerase I inhibitor (exatecan).
ClinicalTrials.gov ID: NCT06238479
HealthScout AI summary: This trial enrolls adults with previously treated advanced MYC-driven or selected solid tumors—including NSCLC, SCLC, high-grade neuroendocrine cancers, L- or N-MYC amplified solid tumors, or diffuse large B-cell lymphoma—testing oral MRT-2359, a GSPT1-targeting molecular glue degrader, as monotherapy or in combination with fulvestrant (HR+/HER2- breast cancer) or enzalutamide (prostate cancer).
ClinicalTrials.gov ID: NCT05546268
HealthScout AI summary: This trial enrolls adults with advanced or metastatic ER+ HER2- breast cancer, mCRPC, or NSCLC who have progressed after standard therapies, to receive OP-3136, an oral selective KAT6A/B inhibitor targeting key epigenetic regulators, as monotherapy. Eligible patients must have unresectable disease or no further effective standard treatment options.
ClinicalTrials.gov ID: NCT06784193
HealthScout AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors—including a wide range such as head and neck, lung, bladder, prostate, breast, colorectal, and others—who have progressed on or are intolerant to standard therapies. Patients receive MGC026, a B7-H3-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor (exatecan), with cohorts in both dose escalation and expansion phases.
ClinicalTrials.gov ID: NCT06242470
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors who have progressed after standard therapies to receive DB-1310, a HER3-targeting antibody-drug conjugate with a topoisomerase I inhibitor payload, as monotherapy or in combination with trastuzumab (HER2+ breast cancer) or osimertinib (EGFR-mutant NSCLC). Key eligibility includes measurable disease, ECOG 0-1, and no prior HER3-ADC or topoisomerase I inhibitor exposure.
ClinicalTrials.gov ID: NCT05785741